饥饿对小鼠脑中tau蛋白磷酸化和O-GlcNAc糖基化的影响

为了探讨大脑中葡萄糖摄取和代谢障碍在阿尔茨海默病(Alzheimer$sdisease,AD)神经退行性病变中的作用,将昆明种小鼠进行饥饿和再喂食处理,并使用多种磷酸化tau蛋白特异性的抗体和蛋白O-GlcNAc糖基化特异性抗体进行检测,观察饥饿及恢复喂养后不同时间点大脑皮质中tau蛋白糖基化及多个位点磷酸化的变化.结果显示:饥饿处理引起小鼠大脑皮质中总蛋白和tau蛋白的O-GlcNAc糖基化水平降低,同时tau蛋白磷酸化水平升高,饥饿引起的tauO-GlcNAc糖基化和磷酸化改变均在恢复进食后逆转成正常水平.该研究结果提示:大脑中tau蛋白的磷酸化和O-GlcNAc糖基化之间存在相互调节,脑中葡萄糖代谢障碍可能通过下调tau蛋白O-GlcNAc糖基化水平使tau蛋白产生异常过度磷酸化,进而促发AD的病理进程.这一结果为在早期阶段通过逆转tau蛋白异常过度磷酸化治疗AD成为可能提供了实验基础.     

O-GlcNAc修饰对蛋白质泛素化降解途径的影响

O-GlcNAc修饰是一种特殊的糖基化修饰,几乎参与生物体内所有细胞过程的调控。该修饰与泛素化作为两种重要的蛋白质翻译后修饰形式,都与2型糖尿病、神经退行性疾病、癌症等疾病密切相关。O-GlcNAc修饰对蛋白质泛素化降解途径的影响主要体现在4个方面:(1)O-GlcNAc修饰能够抑制26S蛋白酶体的ATPase活性;(2)O-GlcNAc修饰会减少某些底物蛋白的泛素化降解;(3)O-GlcNAc修饰泛素化相关酶并调节其功能;(4)某些蛋白质(包括调控因子)发生O-GlcNAc修饰后间接影响蛋白质泛素化。     

O-GlcNAc修饰与肿瘤发生及转移

O-连接的β-N-乙酰葡糖胺（O-GlcNAc）修饰是一种广泛存在于细胞浆和细胞核蛋白质丝/苏氨酸上的动态、可逆的翻译后修饰. 这种修饰与经典的糖基化不同而类似于磷酸化修饰,它在生命过程中发挥重要的调节作用. O-GlcNAc修饰作为潜在的营养感受器,可以调节转录、代谢等众多细胞进程,并与癌症等人类重大疾病密切相关. 本文主要综述了O-GlcNAc修饰与肿瘤形成和转移的关系,并对O-GlcNAc促进肿瘤形成与转移的潜在分子机制进行了探讨.     

葡糖酰胺(O-GlcNAc)修饰:细胞内糖基化的前世今生

糖基化是一种古老的蛋白质翻译后修饰,常见于细胞外的糖被结构和细胞内部的内质网和高尔基体内。近年来,一种细胞内的糖基化修饰逐渐被大家所认识,这就是氧连接的N-乙酰葡糖胺(O-linkedβ-N-acetylglucosamine,O-GlcNAc)。它是唯一发生在细胞内的参与信号转导的糖修饰,一般发生于细胞质和细胞核中。自从20世纪80年代发现O-GlcNAc以来,生物学家和化学家一直在研究它修饰的位点和行使的生物学功能。O-GlcNAc修饰发生在丝氨酸和苏氨酸上,因此可以与磷酸化之间形成阴阳关系并参与信号转导过程。但由于其低丰度易水解的特点导致难以鉴定位点,又使研究人员难以见其真容。本文将回顾O-GlcNAc修饰的发现历史,介绍近年来发展的化学生物学手段对其位点的鉴定,并着重阐释该修饰在细胞周期以及表观遗传等生物过程中的功能。随着学科交叉及质谱技术的发展,古老而弥新的糖基化修饰将绽放出新的花蕾。     

阿尔次海默病tau蛋白异常修饰与其功能的关系

阿尔次海默病易溶型胞浆tau和难溶型双螺旋丝中的tau均被异常磷酸化和异常糖基化修饰.异常修饰的tau丧失其促微管组装活性,用不同蛋白磷酸酯酶对难溶型双螺旋丝中的tau去磷酸化处理后可不同程度恢复其促微管组装生物学活性.单纯去糖基化处理只在很小限度恢复tau的功能,但去糖基化预处理可增强去磷酸化对tau上述活性的恢复.提示:a.tau的异常磷酸化是导致其功能活性丧失的直接因素,而糖基化修饰可能通过对其结构的影响而间接对tau功能活性发挥作用;b.蛋白磷酸酯酶可部分抑制和逆转阿尔次海默病的脑病理损伤.     

植物蛋白质O-糖基化修饰的研究进展

糖基化是最主要的蛋白质翻译后修饰方式之一,主要有N-糖基化、O-糖基化和糖基磷脂酰肌醇锚定修饰三种类型。在植物细胞中, O-糖基化修饰广泛发生,它不仅参与蛋白质转录调节、信号转导,还与细胞壁合成等生物学过程紧密相关。在多种O-糖基化修饰类型中, O-N-乙酰氨基葡萄糖(O-GlcNAc)糖基化修饰结构独特、易于检测和表征,因此已经有许多相关技术实现了对其的表征。然而,其他类型O-糖基化修饰蛋白的结构和功能仍有待更全面的研究。该文综述了植物蛋白中不同类型O-糖基化修饰的相关研究进展,总结了植物O-糖基化修饰蛋白检测技术的优缺点,最后展望了这些技术在植物蛋白质O-糖基化修饰研究中的应用前景。     

蛋白质O-GlcNAc修饰的检测技术

O-连接的N-乙酰葡糖胺（O-GlcNAc）修饰是位于细胞浆和细胞核蛋白质的丝氨酸或苏氨酸上的一种翻译后修饰,在高等真核生物细胞中广泛存在.越来越多的研究表明,O-GlcNAc修饰在代谢调控、压力应激、细胞周期、凋亡、糖尿病、心血管疾病和癌症等多种生理和病理过程中发挥重要作用,因此, O-GlcNAc修饰已受到众多生命科学领域研究人员的关注.然而,由于O-GlcNAc修饰与传统的N聚糖和O聚糖修饰有所不同,常规糖基化修饰的检测方法并不适用于O-GlcNAc.本文对O-GlcNAc修饰的检测及其修饰位点的确定方法进行了综述,并分析了各种方法的优缺点.     

O-乙酰氨基葡萄糖(O-GlcNAc)修饰及其生物学功能研究进展

O-GlcNAc修饰系发生在蛋白质丝氨酸、苏氨酸羟基末端连接的乙酰氨基葡萄糖上的单糖基修饰。自1984年以来,针对O-GlcNAc糖基化修饰的研究日益升温。O-GlcNAc修饰是动态变化、可调控的,满足蛋白质翻译后修饰参与信号通路的必要条件。在多数情况下,O-GlcNAc修饰与磷酸化修饰发生在蛋白质的相同氨基酸残基上,故两种修饰之间常存在竞争性抑制,亦被称之为"阴阳"制衡。O-GlcNAc修饰参与细胞内多种信号通路的调控,调节着生长、增殖、激素响应等过程,在糖尿病、神经退行性疾病和肿瘤等代谢性疾病中扮演重要角色。探究O-GlcNAc修饰及其在生理、病理状态中的作用具有极为重要的意义。     

O-GlcNAc糖基化修饰调控炎症信号通路

O-GlcNAc糖基化修饰指蛋白质的丝氨酸或苏氨酸羟基末端上发生的N-乙酰氨基葡萄糖修饰。O-GlcNAc糖基化修饰广泛影响激酶活性、转录翻译、蛋白质降解等重要生物学途径,但该修饰如何调控炎症信号通路鲜有系统总结。O-GlcNAc糖基化修饰在对应酶作用下数分钟内即可完成一次循环。该修饰与磷酸化、泛素化、甲基化等多种蛋白质翻译后修饰存在串音干扰,共同操控细胞信号通路。目前,O-GlcNAc糖基化修饰参与炎症过程研究大部分聚焦于TLR4/NF-κB信号通路,发现p65蛋白的T352及T305位点的O-GlcNAc糖基化修饰均可促进其核转位,而p65的S536位点发生O-GlcNAc糖基化修饰可抑制其磷酸化激活;亦揭示了O-GlcNAc糖基化修饰调控NF-κB多种上下游因子,改变巨噬细胞极化及炎症反应过程。此外,O-GlcNAc糖基化修饰可干预MAPKs上游激酶(例如MEK2和Ras蛋白等)间接调控MAPKs的激活。O-GlcNAc糖基化修饰不仅深度影响PI3K/AKT多个关键激酶,还可直接调节JAK/STAT信号通路相关的炎症转录因子。真实炎症反应涉及的信号通路远比细胞更复杂和更广泛。体内研究证实,O-GlcNAc糖基化修饰在胰腺、肝、脂肪、肺和肠道等部位的炎性病变中有重要作用。最新研究发现,具备类似O-GlcNAc糖基水解酶活性的肠道细菌,能有效预防宿主结肠炎的发生,证明O-GlcNAc糖基化修饰可介导肠道菌群与宿主炎症相互作用。现有研究结果提示了靶向O-GlcNAc糖基化修饰能为防治炎性疾病提供创新思路。     

蛋白质O-GlcNAc糖基化及其细胞生物学功能

糖基化是蛋白质翻译后修饰的一项重要内容,大多数蛋白质糖基化发生在细胞膜表面,且糖链结构复杂。而发生在细胞浆与细胞核内的、单个O-GlcNAc修饰的蛋白质糖基化现象,因其独特的细胞定位、糖链连接方式以及重要的生物学调控作用而日益成为糖生物学领域研究的热点。现对蛋白质O-GlcNAc修饰及其细胞生物学功能研究进展情况进行综述。     

Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation

Abnormal hyperphosphorylation of microtubule-associated protein tau plays a crucial role in neurodegeneration in Alzheimer's disease (AD). The aggregation of hyperphosphorylated tau into neurofibrillary tangles is also a hallmark brain lesion of AD. Tau phosphorylation is regulated by tau kinases, tau phosphatases, and O-GlcNAcylation, a posttranslational modification of proteins on the serine or threonine residues with β-N-acetylglucosamine (GlcNAc). O-GlcNAcylation is dynamically regulated by O-GlcNAc transferase, the enzyme catalyzing the transfer of GlcNAc to proteins, and N-acetylglucosaminidase (OGA), the enzyme catalyzing the removal of GlcNAc from proteins. Thiamet-G is a recently synthesized potent OGA inhibitor, and initial studies suggest it can influence O-GlcNAc levels in the brain, allowing OGA inhibition to be a potential route to altering disease progression in AD. In this study, we injected thiamet-G into the lateral ventricle of mice to increase O-GlcNAcylation of proteins and investigated the resulting effects on site-specific tau phosphorylation. We found that acute thiamet-G treatment led to a decrease in tau phosphorylation at Thr181, Thr212, Ser214, Ser262/Ser356, Ser404 and Ser409, and an increase in tau phosphorylation at Ser199, Ser202, Ser396 and Ser422 in the mouse brain. Investigation of the major tau kinases showed that acute delivery of a high dose of thiamet-G into the brain also led to a marked activation of glycogen synthase kinase-3β (GSK-3β), possibly as a consequence of down-regulation of its upstream regulating kinase, AKT. However, the elevation of tau phosphorylation at the sites above was not observed and GSK-3β was not activated in cultured adult hippocampal progenitor cells or in PC12 cells after thiamet-G treatment. These results suggest that acute high-dose thiamet-G injection can not only directly antagonize tau phosphorylation, but also stimulate GSK-3β activity, with the downstream consequence being site-specific, bi-directional regulation of tau phosphorylation in the mammalian brain.     

Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases

Tau is a neuronal microtubule-associated protein. Its hyperphosphorylation plays a critical role in Alzheimer disease (AD). Expression and phosphorylation of tau are regulated developmentally, but its dynamic regulation and the responsible kinases or phosphatases remain elusive. Here, we studied the developmental regulation of tau in rats during development from embryonic day 15 through the age of 24 months. We found that tau expression increased sharply during the embryonic stage and then became relatively stable, whereas tau phosphorylation was much higher in developing brain than in mature brain. However, the extent of tau phosphorylation at seven of the 14 sites studied was much less in developing brain than in AD brain. Tau phosphorylation during development matched the period of active neurite outgrowth in general. Tau phosphorylation at various sites had different topographic distributions. Several tau kinases appeared to regulate tau phosphorylation collectively at overlapping sites, and the decrease of overall tau phosphorylation in adult brain might be due to the higher levels of tau phosphatases in mature brain. These studies provide new insight into the developmental regulation of site-specific tau phosphorylation and identify the likely sites required for the abnormal hyperphosphorylation of tau in AD.     

Developmental Regulation of Protein O-GlcNAcylation, O-GlcNAc Transferase, and O-GlcNAcase in Mammalian Brain

O-GlcNAcylation is a common posttranslational modification of nucleocytoplasmic proteins by β-N-acetylglucosamine (GlcNAc). The dynamic addition and removal of O-GlcNAc groups to and from proteins are catalyzed by O-linked N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) and β-N-acetylglucosaminidase (O-GlcNAcase, OGA), respectively. O-GlcNAcylation often modulates protein phosphorylation and regulates several cellular signaling and functions, especially in the brain. However, its developmental regulation is not well known. Here, we studied protein O-GlcNAcylation, OGT, and OGA in the rat brain at various ages from embryonic day 15 to the age of 2 years. We found a gradual decline of global protein O-GlcNAcylation during developmental stages and adulthood. This decline correlated positively to the total protein phosphorylation at serine residues, but not at threonine residues. The expression of OGT and OGA isoforms was regulated differently at various ages. Immunohistochemical studies revealed ubiquitous distribution of O-GlcNAcylation at all ages. Strong immunostaining of O-GlcNAc, OGT, and OGA was observed mostly in neuronal cell bodies and processes, further suggesting the role of O-GlcNAc modification of neuronal proteins in the brain. These studies provide fundamental knowledge of age-dependent protein modification by O-GlcNAc and will help guide future studies on the role of O-GlcNAcylation in the mammalian brain.     

Global Identification and Characterization of Both O-GlcNAcylation and Phosphorylation at the Murine Synapse

O-linked N-acetylglucosamine (O-GlcNAc) is a dynamic, reversible monosaccharide modifier of serine and threonine residues on intracellular protein domains. Crosstalk between O-GlcNAcylation and phosphorylation has been hypothesized. Here, we identified over 1750 and 16,500 sites of O-GlcNAcylation and phosphorylation from murine synaptosomes, respectively. In total, 135 (7%) of all O-GlcNAcylation sites were also found to be sites of phosphorylation. Although many proteins were extensively phosphorylated and minimally O-GlcNAcylated, proteins found to be extensively O-GlcNAcylated were almost always phosphorylated to a similar or greater extent, indicating the O-GlcNAcylation system is specifically targeting a subset of the proteome that is also phosphorylated. Both PTMs usually occur on disordered regions of protein structure, within which, the location of O-GlcNAcylation and phosphorylation is virtually random with respect to each other, suggesting that negative crosstalk at the structural level is not a common phenomenon. As a class, protein kinases are found to be more extensively O-GlcNAcylated than proteins in general, indicating the potential for crosstalk of phosphorylation with O-GlcNAcylation via regulation of enzymatic activity.     

Non-proline-dependent protein kinases phosphorylate several sites found in tau from Alzheimer disease brain

Of 21 phosphorylation sites identified in PHF-tau 11 are on ser/thr-X motifs and are probably phosphorylated by non-proline-dependent protein kinases (non-PDPKs). The identities of the non-PDPKs and how they interact to hyperphosphorylate PHF-tau are still unclear. In a previous study we have shown that the rate of phosphorylation of human tau 39 by a PDPK (GSK-3) was increased several fold if tau were first prephosphorylated by non-PDPKs (Singh et al., FEBS Lett 358: 267-272, 1995). In this study we have examined how the specificity of a non-PDPK for different sites on human tau 39 is modulated when tau is prephosphorylated by other non-PDPKs (A-kinase, C-kinase, CK-1, CaM kinase II) as well as a PDPK (GSK-3). We found that the rate of phosphorylation of tau 39 by a non-PDPK can be stimulated if tau were first prephosphorylated by other non-PDPKs. Of the four non-PDPKs only CK-1 can phosphorylate sites (thr 231, ser 396, ser 404) known to be present in PHF-tau. Further, these sites were phosphorylated more rapidly and to a greater extent by CK-1 if tau 39 were first prephosphorylated by A-kinase, CaM kinase II or GSK-3. These results suggest that the site specificities of the non-PDPKs that participate in PHF-tau hyperphosphorylation can be modulated at the substrate level by the phosphorylation state of tau.Abbreviations PHF paired helical filaments - A-kinase cyclic AMP-dependent protein kinase - CaM kinase II calcium/calmodulin-dependent protein kinase II - C-kinase calcium/phospholipid-dependent protein kinase - CK-1 casein kinase-1 - CK-2 casein kinase-2 - GSK-3 glycogen synthase kinase-3 - MAP kinase mitogen-activated protein kinase - PDPK proline-dependent protein kinase     

运动与阿尔茨海默病：基于Tau蛋白翻译后修饰视角的研究述评

阿尔茨海默病（Alzheimer’s disease,AD）是一种与年龄有关的神经退行性疾病,严重危害老年人的身心健康,给社会带来巨大的经济压力。但目前其发病机制尚不完全明确,临床仍无根治的有效方法。Tau蛋白是一种微管相关蛋白质,能够参与维持微管相关结构稳定,具有可溶性且不会聚集。在AD病理状态下,病人脑内Tau蛋白结构和功能异常。异常的Tau蛋白聚集成不可溶的神经纤维缠结,损害微管运输能力,导致病人认知功能障碍。Tau蛋白结构和功能的改变是由多种翻译后修饰过程来调控的,即将特定的化学修饰基团与Tau蛋白N-端或C-端结合,直接改变蛋白质的性质和功能。AD病人脑内Tau蛋白的磷酸化、糖基化、乙酰化及SUMO化等多种翻译后修饰异常,与Tau蛋白的降解和毒性物质的聚集密切相关。本文综述近年来的研究后发现,运动可以通过改善Tau蛋白翻译后的某些异常修饰来预防和改善AD,主要作用方式如下：(1）运动可通过抑制GSK 3β和MAPK等蛋白激酶活性来抑制Tau蛋白的过度磷酸化,可能通过上调PP2A活性来促进Tau蛋白去磷酸化;(2）运动可通过提高GLUT1和GLUT3蛋白质水平,可能通过调节OGA和OGT活性平衡,提高蛋白质O-GlcNAc糖基化水平;(3）运动可能通过AMPK/mTORC1途径抑制p300以及激活SIRT1,降低Tau蛋白乙酰化水平;同时运动还可能通过抑制HDAC6,改善Tau蛋白KXGS基序异常乙酰化程度;(4）运动可能通过调节磷酸化与SUMO化共定位点,改善Tau蛋白异常SUMO化水平。     

Pseudophosphorylation of tau protein alters its ability for self-aggregation

Filamentous tau protein deposits are a pathological hallmark of a group of neurodegenerative disorders (tauopathies). Tau protein in these aggregates is highly phosphorylated at different phosphorylation sites. Although tau filaments can be formed by heparin-induced aggregation of unphosphorylated recombinant tau, it is not known how tau phosphorylation modulates aggregation behaviour. Analysis of the effect of tau phosphorylation at defined single or multiple sites is hampered by the low specificity of protein kinases and the highly dynamic turnover of phosphorylation in vivo. To overcome this problem we employed site-directed mutagenesis to convert serine and threonine to aspartic acid or glutamic acid, which introduce a negative charge and conformational change that mimic phosphorylation. We tested 14 different mutated tau proteins for their propensity for self-aggregation and formation of tau filaments. Tau aggregation was monitored with thioflavin S fluorescence in the presence of different inducers such as heparin, Al3+, Fe2+ and Fe3+. We found that mutations in the N-terminal portion up to amino acid 208 mainly suppress tau aggregation, whereas mutations in the C-terminal region mainly lead to an enhanced aggregation. Mutations in the middle portion of tau showed a mixed picture of suppression and enhancement of aggregation. A single amino acid change Ser422Glu has aggregation-favouring properties with all four inducers.